FY2029 EPS Estimates for Innate Pharma Decreased by Analyst

Innate Pharma S.A. (NASDAQ:IPHA - Free Report) - Investment analysts at HC Wainwright cut their FY2029 earnings per share estimates for shares of Innate Pharma in a report issued on Thursday, April 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.53 per share for the year, down from their prior estimate of $0.57. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock.

Innate Pharma Price Performance

IPHA traded up $0.02 during trading on Friday, reaching $2.22. The company's stock had a trading volume of 9,451 shares, compared to its average volume of 183,915. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51. The company's fifty day moving average price is $1.98 and its 200-day moving average price is $1.89.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.